MAPT and Alzheimer disease: These effects include a synergistic improvement in brain glucose metabolism through increasing the level of IGF1, BDNF, and GLUT4 proteins involved in glucose metabolism, as well as an improvement in AD pathophysiology (for example, a reduction in p-tau and Aβ load).